149 related articles for article (PubMed ID: 38019248)
1. Association of ABCG2 Polymorphisms on Triple Negative Breast Cancer (TNBC) Susceptibility Risk.
Hao Ing Y; Md Salleh MS; Yahya MM; Ankathil R; Abdul Aziz AA
Asian Pac J Cancer Prev; 2023 Nov; 24(11):3891-3897. PubMed ID: 38019248
[TBL] [Abstract][Full Text] [Related]
2. Association of ABCB1 and ABCG2 single nucleotide polymorphisms with clinical findings and response to chemotherapy treatments in Kurdish patients with breast cancer.
Ghafouri H; Ghaderi B; Amini S; Nikkhoo B; Abdi M; Hoseini A
Tumour Biol; 2016 Jun; 37(6):7901-6. PubMed ID: 26700668
[TBL] [Abstract][Full Text] [Related]
3. Friend or foe: ABCG2, ABCC1 and ABCB1 expression in triple-negative breast cancer.
Nedeljković M; Tanić N; Prvanović M; Milovanović Z; Tanić N
Breast Cancer; 2021 May; 28(3):727-736. PubMed ID: 33420675
[TBL] [Abstract][Full Text] [Related]
4. ABCG2 polymorphisms and susceptibility to ARV-associated hepatotoxicity.
Singh H; Dhotre K; Shyamveer ; Choudhari R; Verma A; Mahajan SD; Ali N
Mol Genet Genomic Med; 2024 Mar; 12(3):e2362. PubMed ID: 38451012
[TBL] [Abstract][Full Text] [Related]
5. ABCG2 polymorphisms, 34G>A and 421C>A in a Korean population: analysis and a comprehensive comparison with other populations.
Kim KA; Joo HJ; Park JY
J Clin Pharm Ther; 2010 Dec; 35(6):705-12. PubMed ID: 21054463
[TBL] [Abstract][Full Text] [Related]
6. Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer.
Akasaka K; Kaburagi T; Yasuda S; Ohmori K; Abe K; Sagara H; Ueda Y; Nagao K; Imura J; Imai Y
Cancer Chemother Pharmacol; 2010 Sep; 66(4):691-8. PubMed ID: 20035425
[TBL] [Abstract][Full Text] [Related]
7. Associations between ABCG2 gene polymorphisms and isolated septal defects in a Han Chinese population.
Wang C; Xie L; Li H; Li Y; Mu D; Zhou R; Liu R; Zhou K; Hua Y
DNA Cell Biol; 2014 Oct; 33(10):689-98. PubMed ID: 24979295
[TBL] [Abstract][Full Text] [Related]
8. Dihydrotestosterone Induces Chemo-Resistance of Triple-Negative Breast MDA-MB-231 Cancer Cells Towards Doxorubicin Independent of ABCG2 and miR-328-3p.
Al-Momany B; Hammad H; Ahram M
Curr Mol Pharmacol; 2021; 14(5):860-870. PubMed ID: 34061013
[TBL] [Abstract][Full Text] [Related]
9. Influence of ABCB1 and ABCG2 polymorphisms on doxorubicin disposition in Asian breast cancer patients.
Lal S; Wong ZW; Sandanaraj E; Xiang X; Ang PC; Lee EJ; Chowbay B
Cancer Sci; 2008 Apr; 99(4):816-23. PubMed ID: 18377430
[TBL] [Abstract][Full Text] [Related]
10. Genetic Variations in ABCG2 Gene Predict Breast Carcinoma Susceptibility and Clinical Outcomes after Treatment with Anthracycline-Based Chemotherapy.
Wu H; Liu Y; Kang H; Xiao Q; Yao W; Zhao H; Wang E; Wei M
Biomed Res Int; 2015; 2015():279109. PubMed ID: 26634205
[TBL] [Abstract][Full Text] [Related]
11. Polymorphisms of
Duong NT; Ngoc NT; Thang NTM; Phuong BTH; Nga NT; Tinh ND; Quynh DH; Ton ND; Hai NV
Medicina (Kaunas); 2019 Jan; 55(1):. PubMed ID: 30621105
[No Abstract] [Full Text] [Related]
12. Association of ABCB1, ABCG2 drug transporter polymorphisms and smoking with disease risk and cytogenetic response to imatinib in chronic myeloid leukemia patients.
Mohammadi F; Rostami G; Hamid M; Shafiei M; Azizi M; Bahmani H
Leuk Res; 2023 Mar; 126():107021. PubMed ID: 36696828
[TBL] [Abstract][Full Text] [Related]
13. A comprehensive analysis of the association of common variants of ABCG2 with gout.
Yu KH; Chang PY; Chang SC; Wu-Chou YH; Wu LA; Chen DP; Lo FS; Lu JJ
Sci Rep; 2017 Aug; 7(1):9988. PubMed ID: 28855613
[TBL] [Abstract][Full Text] [Related]
14. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
Tandia M; Mhiri A; Paule B; Saffroy R; Cailliez V; Noé G; Farinotti R; Bonhomme-Faivre L
Cancer Chemother Pharmacol; 2017 Apr; 79(4):759-766. PubMed ID: 28289864
[TBL] [Abstract][Full Text] [Related]
15. ABCB1 gene polymorphisms, ABCB1 haplotypes and ABCG2 c.421c > A are determinants of inter-subject variability in rosuvastatin pharmacokinetics.
Zhou Q; Ruan ZR; Yuan H; Xu DH; Zeng S
Pharmazie; 2013 Feb; 68(2):129-34. PubMed ID: 23469685
[TBL] [Abstract][Full Text] [Related]
16. Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
Tamura M; Kondo M; Horio M; Ando M; Saito H; Yamamoto M; Horio Y; Hasegawa Y
Nagoya J Med Sci; 2012 Feb; 74(1-2):133-40. PubMed ID: 22515119
[TBL] [Abstract][Full Text] [Related]
17. Clinical utility of ABCB1 and ABCG2 genotyping for assessing the clinical and pathological response to FAC therapy in Mexican breast cancer patients.
Turiján-Espinoza E; Ruíz-Rodríguez VM; Uresti-Rivera EE; Martínez-Leija E; Zermeño-Nava JJ; Guel-Pañola A; Romano-Moreno S; Vargas-Morales JM; Portales-Pérez DP
Cancer Chemother Pharmacol; 2021 Jun; 87(6):843-853. PubMed ID: 33740100
[TBL] [Abstract][Full Text] [Related]
18. Impact of ABCB1, ABCC1, ABCC2, and ABCG2 variants in predicting prognosis and clinical outcomes of north Indian lung cancer patients undergoing platinum-based doublet chemotherapy.
Sharma P; Singh N; Sharma S
J Gene Med; 2023 Jan; 25(1):e3460. PubMed ID: 36314103
[TBL] [Abstract][Full Text] [Related]
19. Impact of
Huang YH; See LC; Chang YC; Chung WH; Chang LC; Yang SF; Su SC
Genes (Basel); 2021 Oct; 12(10):. PubMed ID: 34680995
[TBL] [Abstract][Full Text] [Related]
20.
Božina T; Ganoci L; Karačić E; Šimičević L; Vrkić-Kirhmajer M; Klarica-Domjanović I; Križ T; Sertić Z; Božina N
Ann Hum Biol; 2022 Dec; 49(7-8):323-331. PubMed ID: 36382878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
